Secondary outcomes
The secondary outcomes are described in details in the study protocol
(19).
The following secondary outcomes were self-reported:
Psychological well-being, measured by WHO-5 eight weeks postpartum. In
the planning of the trial this secondary was the highest prioritised
secondary outcome (19). The remaining secondary outcomes were not
ranked.Functional ability, measured by General Health Questionnaire
(GHQ-12), clinical symptoms of anxiety, measured by the Spielberger
State-Trait Anxiety Inventory (STAI), symptoms of depression defined as
a cut-off score of ≥11 on the Edinburgh Postnatal Depression Scale
(EPDS) were all measured 29–34 weeks of gestation and eight weeks
postpartum. Based on a resent Danish study validating the Danish version
of the EPDS against a diagnosis of depression in a sample of new
mothers, we changed our predefined cut-off scores of ≥10 and ≥13 on the
EPDS to a cut-off score of ≥11 (23). Further self-reported secondary
outcomes were exclusive breastfeeding at eight weeks postpartum and sick
leave in days from intervention start until labour.
The following secondary outcomes were obtained from medical records:
Preeclampsia, gestational age (days) at delivery, preterm delivery
(> three weeks before term), induction of labour, mode of
delivery (spontaneous delivery, instrumental delivery, or caesarean
section), epidural anesthesia during delivery, duration of labour
(hours), birth weight (gram), birth length (centimeters), Apgar score
(<7 at 5 min), arterial pH (<7.10), antenatal
contacts (number), antenatal telephone consultations (number), and
length of hospital stay (days).
All secondary outcomes are describes in details in the study protocol
(19).